Whitehawk Therapeutics (WHWK) EBT Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) posted quarterly EBT Margin of 1021.92% for Q1 2025, up 138943.0% year-over-year from N/an in Q1 2024, and up 577.82% quarter-over-quarter from 213.87% in Q4 2024.
Powered by 
Analysis
Whitehawk Therapeutics (WHWK) EBT Margin (2018 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported EBT Margin for 7 consecutive years, with 1021.92% the latest figure, recorded in Q1 2025.
- In Q1 2025, EBT Margin rose 138943.0% year-over-year to 1021.92%; the TTM figure through Dec 2025 stood at 416.0% (down 17032.0% YoY), while the FY2025 annual figure was 288.26%, down 4313.0% from the prior year.
- EBT Margin rose to 1021.92% in Q1 2025 per WHWK's latest filing, from 213.87% in the prior quarter.
- Across five years, EBT Margin topped out at 1021.92% in Q1 2025 and bottomed at 4563.33% in Q1 2021.
- Historically, EBT Margin has averaged 499.46% across 5 years, with a median of 266.35% in 2022.
- Annual changes were most pronounced in 2021 — EBT Margin sank 17151 bps — and 2022, when it soared 396268 bps.
- Whitehawk Therapeutics' EBT Margin stood at 114.21% in 2021, then plunged by 133 bps to 266.35% in 2022, then gained by 3 bps to 257.18% in 2023, then advanced by 17 bps to 213.87% in 2024, then soared by 578 bps to 1021.92% in 2025.
- Business Quant data shows WHWK's EBT Margin at 1021.92% in Q1 2025, 213.87% in Q4 2024, and 177.44% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Whitehawk Therapeutics | 377.13 Mn | 377.13 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 1,021.92% |
| Dec 31, 2024 | -252.42% |
| Sep 30, 2024 | -173.95% |
| Jun 30, 2024 | -253.46% |
| Mar 31, 2024 | -366.24% |
| Dec 31, 2023 | -257.18% |
| Sep 30, 2023 | -273.57% |
| Jun 30, 2023 | -289.76% |
| Mar 31, 2023 | -259.47% |
| Dec 31, 2022 | -266.35% |
| Sep 30, 2022 | -340.97% |
| Jun 30, 2022 | -531.28% |
| Mar 31, 2022 | -600.65% |
| Dec 31, 2021 | -114.21% |
| Mar 31, 2021 | -4,563.33% |
| Dec 31, 2020 | 57.29% |
| Sep 30, 2020 | -1,251.52% |
| Jun 30, 2020 | 61.84% |
| Dec 31, 2018 | -397,322.25% |
| Sep 30, 2018 | 61.26% |